LY3537021
Phase 2Small molecule
Eli LillyLY3537021 is one of 68 small molecule programs targeting Type 2 Diabetes Mellitus. It is currently in Phase 2.
3
Indications
3
Total Trials
1
Active Trials
67
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
676 competitors in Type 2 Diabetes Mellitus
#DrugCompanyPhaseTrials
1Byetta
AstraZenecaPreclinical
Tanzeum
GSKPreclinical
Insulin 320
Novo NordiskPreclinical
Adenocard
AstellasPreclinical
LY3537021
Eli LillyPhase 2
Dostinex
PfizerPreclinical
Golytely
BayerPreclinical
Cipro
BayerPreclinical
Myrbetriq
AstellasPreclinical
Lantus
SanofiPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LY3537021. EMBL-EBI & Wellcome Sanger Institute.
- [4]